These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 22266871)

  • 1. Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair.
    Kudo K; Gavin E; Das S; Amable L; Shevde LA; Reed E
    Oncogene; 2012 Nov; 31(44):4718-24. PubMed ID: 22266871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene.
    Yu JJ; Lee KB; Mu C; Li Q; Abernathy TV; Bostick-Bruton F; Reed E
    Int J Oncol; 2000 Mar; 16(3):555-60. PubMed ID: 10675489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MZF1 possesses a repressively regulatory function in ERCC1 expression.
    Yan QW; Reed E; Zhong XS; Thornton K; Guo Y; Yu JJ
    Biochem Pharmacol; 2006 Mar; 71(6):761-71. PubMed ID: 16426580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absence of evidence for allelic loss or allelic gain for ERCC1 or for XPD in human ovarian cancer cells and tissues.
    Yu JJ; Bicher A; Ma YK; Bostick-Bruton F; Reed E
    Cancer Lett; 2000 Apr; 151(2):127-32. PubMed ID: 10738106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Relationship between nucleotide excision repair gene ERCC1 and resistance to cisplatin in ovarian cancer].
    Liu GY; Qu QX; Mi RR; Qi J
    Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):184-7. PubMed ID: 18756932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lentivirus-Mediated RNAi silencing targeting ERCC1 reverses cisplatin resistance in cisplatin-resistant ovarian carcinoma cell line.
    Du P; Zhang X; Liu H; Chen L
    DNA Cell Biol; 2015 Jul; 34(7):497-502. PubMed ID: 25941922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.
    Selvakumaran M; Pisarcik DA; Bao R; Yeung AT; Hamilton TC
    Cancer Res; 2003 Mar; 63(6):1311-6. PubMed ID: 12649192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro studies on the mechanisms of oxaliplatin resistance.
    Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L
    Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotypes and haplotypes of ERCC1 and ERCC2/XPD genes predict levels of benzo[a]pyrene diol epoxide-induced DNA adducts in cultured primary lymphocytes from healthy individuals: a genotype-phenotype correlation analysis.
    Zhao H; Wang LE; Li D; Chamberlain RM; Sturgis EM; Wei Q
    Carcinogenesis; 2008 Aug; 29(8):1560-6. PubMed ID: 18635523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
    Li F; Sun X; Sun N; Qin S; Cheng H; Feng J; Chen B; Cheng L; Lu Z; Ji J; Zhou Y
    Am J Clin Oncol; 2010 Oct; 33(5):489-94. PubMed ID: 20351547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combinatorial treatment of ovarian cancer cells with harringtonine and cisplatin results in increased cisplatin-DNA adducts.
    Yunmbam MK; Guo Y; Miller MR; Yu JJ
    Oncol Rep; 2004 Apr; 11(4):833-8. PubMed ID: 15010881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF.
    Ferry KV; Hamilton TC; Johnson SW
    Biochem Pharmacol; 2000 Nov; 60(9):1305-13. PubMed ID: 11008124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gli1 contributes to cellular resistance to cisplatin through altered cellular accumulation of the drug.
    Amable L; Fain J; Gavin E; Reed E
    Oncol Rep; 2014 Aug; 32(2):469-74. PubMed ID: 24926795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein expression levels of excision repair cross-complementation group 1 and xeroderma pigmentosum D correlate with response to platinum-based chemotherapy in the patients with advanced epithelial ovarian cancer.
    Lin K; Ye D; Xie X
    Int J Gynecol Cancer; 2008; 18(5):1007-12. PubMed ID: 18081788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CITED2 silencing sensitizes cancer cells to cisplatin by inhibiting p53 trans-activation and chromatin relaxation on the ERCC1 DNA repair gene.
    Liu YC; Chang PY; Chao CC
    Nucleic Acids Res; 2015 Dec; 43(22):10760-81. PubMed ID: 26384430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Influence of mifepristone on DNA repair genes and cisplatin sensitivity in human ovarian cancer drug-resistance cells].
    Liu GY; Qu QX; Mi RR; Qi J
    Zhonghua Fu Chan Ke Za Zhi; 2008 Feb; 43(2):132-5. PubMed ID: 18683754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of DNA repair gene expression in human cancer cell lines.
    McGurk CJ; Cummings M; Köberle B; Hartley JA; Oliver RT; Masters JR
    J Cell Biochem; 2006 Apr; 97(5):1121-36. PubMed ID: 16315315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes.
    Bradbury PA; Kulke MH; Heist RS; Zhou W; Ma C; Xu W; Marshall AL; Zhai R; Hooshmand SM; Asomaning K; Su L; Shepherd FA; Lynch TJ; Wain JC; Christiani DC; Liu G
    Pharmacogenet Genomics; 2009 Aug; 19(8):613-25. PubMed ID: 19620936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphisms in ERCC1 and ERCC2/XPD genes and carcinogen DNA adducts in human lung.
    Lee MS; Liu CY; Su L; Christiani DC
    Lung Cancer; 2015 Jul; 89(1):8-12. PubMed ID: 26001533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of genetic markers on survival in non-small cell lung cancer.
    Rosell R; Taron M; Camps C; López-Vivanco G
    Drugs Today (Barc); 2003 Oct; 39(10):775-86. PubMed ID: 14668933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.